India is on the brink of finalizing a free trade agreement with the European Union. Yet even as the deal gets close, one area remains hotly contested: protection for intellectual property (IP). Controversy mounts over "data exclusivity" for pharmaceuticals.

The process of treating HIV patients in Africa has improved markedly due to cooperation between pharmaceutical companies, which has led to increasing access to higher quality medicines.

Some activist groups' rhetoric hurts the search for an AIDS cure.

At issue in Geneva are claims by indigenous and local communities that foreign interests are exploiting their cultural and biological bounties.

Health care is taking up more and more of government budgets globally, and corruption is probably rising faster in health care than almost any other sector.

Should countries should be switching from existing therapies of brand-name drugs to formulations made from knockoff drugs that are simpler for patients to take?

Targeted biotech drugs that attack specific biological molecules that cause disease are bringing new benefitsand fomentingpricing dynamics different from those of traditional drugs.

With the fates of the Food and Drug Administration and the pharmaceutical industry more intertwined than ever, our health depends on regulatory innovation as much as on scientific progress.